Atomwise is a startup that operates in the pharmaceutical industry, leveraging artificial intelligence (AI) to revolutionize drug discovery. The company's primary offering is an AI engine that uses machine learning and convolutional neural networks to sift through vast chemical libraries. This technology enables Atomwise to identify new small molecule medicines more efficiently and effectively than traditional methods.

The company's clients are primarily in the healthcare and pharmaceutical sectors, who are looking for more efficient ways to discover new drugs. Atomwise's business model is based on developing and co-developing pipeline assets, which are then backed by investors. This means that the company makes money by creating and improving medicines, and then selling these discoveries to pharmaceutical companies or healthcare providers.

Atomwise's unique selling point is its combination of AI and machine learning, which allows it to create better medicines faster. This not only reduces the time and cost associated with drug discovery, but also has the potential to improve patient outcomes by delivering more effective treatments.

In conclusion, Atomwise is a forward-thinking startup that is using AI to disrupt the traditional drug discovery process. Its innovative approach has the potential to make a significant impact on the pharmaceutical industry and improve the lives of patients worldwide.

Keywords: Atomwise, Startup, Artificial Intelligence, Machine Learning, Drug Discovery, Pharmaceutical Industry, Healthcare, Convolutional Neural Networks, Small Molecule Medicines, Pipeline Assets.